Complement Factor I
Complement C3b
Complement Factor H
Complement Factor B
In vitro analysis of complement-dependent HIV-1 cell infection using a model system. (1/80)
Previous studies based on the use of human serum as a source of C have provided evidence for the C-dependent enhancement of cell infection by HIV-1. The present study was undertaken to distinguish C from other serum factors and to identify the proteins and the mechanisms involved in C-dependent cell infection by HIV-1. The classical C activation pathway was reconstituted from the proteins C1q, C1r, C1s, C4, C2, C3, factor H, and factor I; each were purified to homogeneity. A mixture of these proteins at physiological concentrations was shown to reproduce the ability of normal human serum to enhance the infection of MT2 cells by HIV-1 at low doses of virus. This enhancing effect was abolished when heat-inactivated serum and C2- or C3-depleted serum were used, and was restored upon addition of the corresponding purified proteins. A mixture of two synthetic peptides corresponding to positions 10-15 and 90-97 of human C receptor type 2 (CD21) as well as soluble CD4 both inhibited the C-dependent infection process. These data provide unambiguous evidence that HIV-1 triggers a direct activation of the classical C pathway in vitro and thereby facilitates the infection of MT2 cells at low doses of virus. These findings are consistent with a mechanism involving increased interaction between the virus opsonized by C3b-derived fragment(s) and the CD21 cell receptors and subsequent virus entry through CD4 receptors. (+info)A cluster of positively charged amino acids in the C4BP alpha-chain is crucial for C4b binding and factor I cofactor function. (2/80)
C4b-binding protein (C4BP) is a regulator of the classical complement pathway, acting as a cofactor to factor I in the degradation of C4b. Computer modeling and structural analysis predicted a cluster of positively charged amino acids at the interface between complement control protein modules 1 and 2 of the C4BP alpha-chain to be involved in C4b binding. Three C4BP mutants, R39Q, R64Q/R66Q, and R39Q/R64Q/R66Q, were expressed and assayed for their ability to bind C4b and to function as factor I cofactors. The apparent affinities of R39Q, R64Q/R66Q, and R39Q/R64Q/R66Q for immobilized C4b were 15-, 50-, and 140-fold lower, respectively, than that of recombinant wild type C4BP. The C4b binding site demonstrated herein was also found to be a specific heparin binding site. In C4b degradation, the mutants demonstrated decreased ability to serve as factor I cofactors. In particular, the R39Q/R64Q/R66Q mutant was inefficient as cofactor for cleavage of the Arg937-Thr938 peptide bond in C4b. In contrast, the factor I mediated cleavage of Arg1317-Asn1318 bond was less affected by the C4BP mutations. In conclusion, we identify a cluster of amino acids that is part of a C4b binding site involved in the regulation of the complement system. (+info)Molecular cloning, expression and characterization of the rat analogue of human membrane cofactor protein (MCP/CD46). (3/80)
In humans, host cells are protected from homologous complement by membrane proteins encoded in the regulators of complement activation (RCA) gene cluster. These include complement receptor 1 (CR1), decay-accelerating factor (DAF, CD55) and membrane cofactor protein (MCP, CD46). In mouse and rat a single membrane inhibitor, Crry, appeared to perform the functions of both DAF and MCP and was proposed to be the functional analogue of both. Recently, however, murine homologues of DAF and MCP have been identified, prompting a search for the rat counterparts. We have described the identification of rat DAF and here describe the cloning of rat MCP from cDNA and genomic libraries, using a probe based on the mouse MCP cDNA sequence. The domain structure for rat MCP was identical to that of mouse MCP with four short consensus repeats (SCRs) followed by a STP domain, transmembrane segment and cytoplasmic tail. Overall identity of rat and mouse MCP was 77% at the amino acid level and 88% at the nucleotide level. Northern blot analysis from a range of tissues indicated that high-level expression was limited to the testis, although expression in other tissues was detected using reverse transcription-polymerase chain reaction. Rat MCP mRNA localized to Sertoli cells and spermatogonia in seminiferous tubules by in situ hybridization, but was absent in mature sperm. In cofactor assays utilizing human factor I, a recombinant soluble form of rat MCP catalysed cleavage of human C3ma. (+info)Function of the factor I modules (FIMS) of human complement component C6. (4/80)
In order to elucidate the function of complement component C6, truncated C6 molecules were expressed recombinantly. These were either deleted of the factor I modules (FIMs) (C6des-748-913) or both complement control protein (CCP) modules and FIMs (C6des-611-913). C6des-748-913 exhibited approximately 60-70% of the hemolytic activity of full-length C6 when assayed for Alternative Pathway activity, but when measured for the Classical Pathway, C6des-748-914 was only 4-6% as effective as C6. The activity difference between C6 and C6des-748-913 for the two complement pathways can be explained by a greater stability of newly formed metastable C5b* when produced by the Alternative Pathway compared with that made by the Classical Pathway. The half-lives of metastable C5b* and the decay of (125)I-C5b measured from cells used to activate the Alternative Pathway were found to be about 5-12-fold longer than those same parameters derived from cells that had activated the Classical Pathway. (125)I-C5 binds reversibly to C6 in an ionic strength-dependent fashion, but (125)I-C5 binds only weakly to C6des-FIMs and not at all to C6des-CCP/FIMs. Therefore, although the FIMs are not required absolutely for C6 activity, these modules promote interaction of C6 with C5 enabling a more efficient bimolecular coupling ultimately leading to the formation of the C5b-6 complex. (+info)Rat complement factor I: molecular cloning, sequencing and expression in tissues and isolated cells. (5/80)
Factor I (FI) is a regulatory serine protease of the complement system which cleaves three peptide bonds in the alpha-chain of C3b and two bonds in the alpha-chain of C4b thereby inactivating these proteins. The human protein and the recently characterized mouse factor I are heterodimers of about 88,000 MW which consist of a non-catalytic heavy chain of 50,000 MW which is linked to a catalytic light chain of 38,000 MW by a disulphide bond. For the screening of a rat liver cDNA library we used a hybridization probe produced by polymerase chain reaction (PCR) using degenerated primers which corresponded to conserved parts of the human and the murine factor I nucleotide sequences. One of the identified sequences, which had a length of 2243 base pairs (bp), contained the complete coding region and the whole 3' untranslated region. The length of the coding region in rat consisted of 1812 bp followed by a 3' untranslated region of 207 bp including the polyadenylation signal and the beginning of the poly A tail. Comparison of the rat cDNA-derived coding sequence revealed identities of 87% to the mouse and of 78% to the human FI nucleotide sequence. The translation product of rat FI mRNA was 604 amino acid residues (aa) in length with an identity of 85% to the mouse (603 aa) and 69% to the human protein (583 aa). The comparison of the molecular mass predicted by the primary structure and derived from rat FI isolated from rat serum as detected in immunoblot analyses suggested a glycosylation of more than 20% of the total mass of the FI protein. Expression studies using reverse transcription (RT)-PCR assays indicated that FI-specific mRNA could neither be identified in B cells, nor in T cells, monocytes or granulocytes from rat and human peripheral blood nor in rat peritoneal macrophages. These data were in agreement with the results of RT-PCR obtained with several human lymphoma cell lines (Jurkat, MOLT-4, HUT102, Wil 2-NS, Ramos, Raji, U937) all of which were devoid of FI-specific mRNA. In accord with our data from two rat hepatoma cell lines (FAO and H4IIE) and one from man (HepG2) only isolated rat hepatocytes (HC) but neither Kupffer cells (KC), hepatic stellate cells (HSC; Ito cells) nor sinusoidal endothelial cells (SEC) expressed FI-specific mRNA. FI mRNA was also detected in human umbilical vein endothelial cells (HUVEC) and in the uterus and small intestine of the rat. Spleen and lymph nodes did not contain any detectable FI-specific mRNA. (+info)Regulation of complement classical pathway by association of C4b-binding protein to the surfaces of SK-OV-3 and Caov-3 ovarian adenocarcinoma cells. (6/80)
The role of fluid-phase regulators of complement is to inhibit excessive complement activation and maintain homeostasis in blood. By binding to and inactivating complement components on cell surfaces, they can also protect autologous cells from complement-mediated cytotoxicity and phagocytosis. In this study, we wanted to find out whether C4b-binding protein (C4bp), a fluid-phase regulator of the classical complement pathway, could directly bind to cell surfaces in a functionally active form. After screening several malignant cell lines, we observed that the ovarian adenocarcinoma cell lines SK-OV-3, Caov-3, and SW626 were capable of binding C4bp. Binding tests with recombinant deletion mutants suggested that the primary binding site on C4bp is located on the alpha-chain complement control protein 4 domain. Functional tests showed that tumor cell-bound C4bp retained its cofactor activity for factor I-mediated inactivation of C4b, thus increasing the control of classical complement pathway activation on the surfaces of these cells. These results demonstrate a novel mechanism of complement regulation on cell surfaces, particularly on those of malignant ovarian tumor cells. (+info)Mapping of the sites responsible for factor I-cofactor activity for cleavage of C3b and C4b on human C4b-binding protein (C4bp) by deletion mutagenesis. (7/80)
Human C4b-binding protein (C4bp) facilitates the factor I-mediated proteolytic cleavage of the active forms of complement effectors C3b and C4b into their inactive forms. C4bp comprises a disulfide-linked heptamer of alpha-chains with complement (C) regulatory activity and a beta-chain. Each alpha-chain contains 8 short consensus repeat (SCR) domains. Using SCR-deletion mutants of recombinant multimeric C4bp, we identified the domains responsible for the C3b/C4b-binding and C3b/C4b-inactivating cofactor activity. The C4bp mutant with deletion of SCR2 lost the C4b-binding ability, as judged on C3b/C4b-Sepharose binding assaying and ELISA. In contrast, the essential domains for C3b-binding extended more to the C-terminus, exceeding SCR4. Using fluid phase cofactor assaying and deletion mutants of C4bp, SCR2 and 3 were found to be indispensable for C4b cleavage by factor I, and SCR1 contributed to full expression of the factor I-mediated C4b cleaving activity. On the other hand, SCR1, 2, 3, 4, and 5 participated in the factor I-cofactor activity for C3b cleavage, and SCR2, 3, and 4 were absolutely required for C3b inactivation. Thus, different sets of SCRs participate in C3b and C4b inactivation, and the domain repertoire supporting C3b cofactor activity is broader than that supporting C4b inactivation by C4bp and factor I. Furthermore, the domains participating in C3b/C4b binding are not always identical to those responsible for cofactor activity. The necessity of the wide range of SCRs in C3b inactivation compared to C4b inactivation by C4bp and factor I may reflect the physiological properties of C4bp, which is mainly directed to C4b rather than C3b. (+info)Human complement factor I does not require cofactors for cleavage of synthetic substrates. (8/80)
Complement factor I (fI) plays a major role in the regulation of the complement system. It circulates in an active form and has very restricted specificity, cleaving only C3b or C4b in the presence of a cofactor such as factor H (fH), complement receptor type 1, membrane cofactor protein, or C4-binding protein. Using peptide-7-amino-4-methylcoumarin derivatives, we investigated the substrate specificity of fI. There is no previous report of synthetic substrate cleavage by fI, but five substrates were found in this study. A survey of 15 substrates and a range of inhibitors showed that fI has specificity similar to that of thrombin, but with much lower catalytic activity than that of thrombin. fI amidolytic activity has a pH optimum of 8.25, typical of serine proteases and is insensitive to ionic strength. This is in contrast to its proteolytic activity within the fI-C3b-fH reaction, in which the pH optimum for C3b cleavage is <5.5 and the reaction rate is highly dependent on ionic strength. The rate of cleavage of tripeptide 7-amino-4-methylcoumarins by fI is unaffected by the presence of fH or C3(NH(3)). The amidolytic activity is inhibited by the synthetic thrombin inhibitor Z-D-Phe-Pro-methoxypropylboroglycinepinanediol ester, consistent with previous reports, and by benzenesulfonyl fluorides such as Pefabloc SC. Suramin inhibits fI directly at concentration of 1 mM. Within a range of metal ions tested, only Cr(2+) and Fe(3+) were found to inhibit both the proteolytic and amidolytic activity of fI. (+info)Complement Factor I (C1) is a protein complex that plays a crucial role in the complement system, which is a part of the immune system that helps to defend the body against infections and remove damaged cells. C1 is composed of three subunits: C1q, C1r, and C1s. When a pathogen enters the body, it triggers the activation of the complement system, which leads to the formation of a cascade of proteins that ultimately results in the destruction of the pathogen. C1 is the first protein in this cascade to be activated, and it plays a critical role in identifying and binding to the pathogen. Once C1 binds to the pathogen, it triggers the activation of C1r and C1s, which then cleave and activate other complement proteins, leading to the formation of a membrane attack complex (MAC) that can directly destroy the pathogen. C1 also plays a role in regulating the complement system by inhibiting its activation in the absence of a pathogen. In summary, Complement Factor I (C1) is a protein complex that plays a critical role in the complement system, which helps to defend the body against infections and remove damaged cells. It is the first protein in the complement cascade to be activated and plays a critical role in identifying and binding to pathogens.
Complement C3b is a protein fragment that is generated when the complement system, a part of the immune system, is activated. The complement system is a complex network of proteins that work together to help the body fight off infections and remove damaged or abnormal cells. C3b is produced when the complement protein C3 is cleaved by enzymes in the complement system. C3b plays an important role in the complement system by binding to the surface of pathogens or damaged cells and marking them for destruction by immune cells. It also helps to recruit immune cells to the site of infection or injury and can activate other components of the complement system to enhance the immune response. In the medical field, C3b is often measured as a marker of complement system activation. Abnormal levels of C3b can be associated with a variety of medical conditions, including autoimmune disorders, infections, and certain types of cancer.
Complement Factor H (CFH) is a protein that plays a critical role in the complement system, which is a part of the immune system that helps to defend the body against infections. CFH is a soluble protein that is present in the blood and helps to regulate the activity of the complement system by inhibiting the formation of the membrane attack complex (MAC), which is a group of proteins that can cause damage to cells and tissues. CFH is also involved in the regulation of inflammation and the immune response, and it has been implicated in a number of diseases, including age-related macular degeneration (AMD), a common eye disorder that can lead to vision loss, and atypical hemolytic uremic syndrome (aHUS), a rare and life-threatening disorder that can cause kidney failure and other complications. In addition to its role in the complement system, CFH has also been shown to have anti-inflammatory and anti-apoptotic effects, and it may play a role in the development of other diseases, such as cancer and neurodegenerative disorders.
Complement Factor B (CFB) is a protein that plays a crucial role in the complement system, which is a part of the immune system that helps to defend the body against infections and remove damaged cells. CFB is a soluble protein that is produced by the liver and circulates in the bloodstream. In the complement system, CFB is involved in the activation of the alternative pathway, which is one of three pathways that can activate the complement system. The alternative pathway is activated when antibodies bind to foreign substances on the surface of cells, and CFB helps to amplify the immune response by promoting the formation of a complex that leads to the activation of other complement proteins. Deficiencies in CFB can lead to a condition called complement factor B deficiency, which can result in recurrent infections and other immune system disorders.
Complement Factor D (CFD) is a protein that plays a crucial role in the complement system, which is a part of the immune system that helps to defend the body against infections and remove damaged cells. CFD is also known as complement factor Bb or membrane attack complex (MAC) convertase. CFD is synthesized in the liver and circulates in the blood as an inactive form. When it encounters a pathogen or damaged cell, it is activated by proteolytic cleavage, which generates two active fragments: C3 convertase and C5 convertase. These convertases cleave other complement proteins, leading to the formation of the membrane attack complex (MAC), which can directly lyse the pathogen or damaged cell. In addition to its role in the complement system, CFD has also been implicated in the development of various diseases, including age-related macular degeneration, atherosclerosis, and systemic lupus erythematosus. Therefore, CFD is an important target for the development of new therapies for these diseases.
Complement factor I
Complement factor B
C3a (complement)
Complement component 3
Complement component 4B
Complement control protein
List of OMIM disorder codes
Complement (group theory)
Properdin deficiency
CFHR5
CFHR4
CFHR2
Nucleolin
IC3b
Genome-wide association study
Complement component 2
Total complement activity
Synovial fluid
James Markusen
Single-nucleotide polymorphism
L-selectin
Iptacopan
Personalized medicine
BioCryst Pharmaceuticals
Tuxedo Computers
Phagoptosis
CD59
Atypical hemolytic uremic syndrome
ARF5
CFHR3
Complement factor I - Wikipedia
Complement factor I deficiency: MedlinePlus Genetics
Complement factor H | BioVendor R&D
Factor D Inhibition Blocks Complement Activation Induced by Mutant Factor B Associated With Atypical Hemolytic Uremic Syndrome...
Complement C4 Deficiency - A Plausible Risk Factor for Non-Tuberculous Mycobacteria (NTM) Infection in Apparently...
Insights from Reliability-Based Design to Complement Load and Resistance Factor Design Approach - New Zealand Geotechnical...
Functional anatomy of complement Factor H - Fingerprint - University of Edinburgh Research Explorer
Complement Factor H: Function and Dysfunction | Abstract
CFIbase: Complement factor I deficiency | Liability
Complement-Related Disorders: Background, Pathophysiology, Activation
Complement C3 nephritic factor - North West London Pathology
Preeclampsia, Hypoxia, Thrombosis, and Inflammation
How endothelial cells protect themselves from complement by expressing decay-accelerating factor (DAF) | Arthritis Research &...
Anti Human Complement Factor H Antibody, clone 028B-244.2.10X (10-10) | Bio-Rad
Interaction of Shiga toxin 2 with complement regulators of the factor H protein family. - Leibniz-HKI
Depression of complex bioelectric discharges in cerebral tissue cultures by thermolabile complement-dependent serum factors<...
ACIP Altered Immunocompetence Guidelines for Immunizations | CDC
Synthesis of complement components C3 and factor B in human keratinocytes is differentially regulated by cytokines. | J Invest...
CspA-mediated binding of human factor H inhibits complement deposition and confers serum resistance in Borrelia burgdorferi. |...
Antibody recognition of complement factor H reveals a flexible loop involved in atypical hemolytic uremic syndrome pathogenesis...
Table 2 - Shiga Toxin-Associated Hemolytic Uremic Syndrome in Adults, France, 2009-2017 - Volume 27, Number 7-July 2021 -...
Serum Amyloid A in Uremic HDL Promotes Inflammation : Journal of the American Society of Nephrology
Vaccines | Free Full-Text | Next-Generation Whole-Cell Pneumococcal Vaccine
Catalog
Paroxysmal Nocturnal Hemoglobinuria: Practice Essentials, Pathophysiology, Etiology
Prognostic phenotypic and genotypic factors associated with photodynam | OPTH
Interaction With Host Pathway Bioinformatics: Novus Biologicals
Anders Wallin | Göteborgs universitet
Retinal Development, Genetics and Therapy Section | National Eye Institute
Effects of inflammatory and anti-inflammatory environments on the macrophage mitochondrial function | Scientific Reports
Proteins14
- Complement factor I and several related proteins protect healthy cells by preventing activation of the complement system when it is not needed. (medlineplus.gov)
- Binding sites, especially for complement receptor (CR3), malondialdehyde (MDA)-modified proteins, and apolipoprotein E (apoE), are dispersed throughout its 20 CCP modules (CCPs), also known as short consensus repeats, to facilitate additional 'non-canonical' FH activities. (imedpub.com)
- The complement system as understood today is a multimolecular system composed of more than 32 proteins and consisting of serum proteins, serosal proteins, and cell membrane receptors that bind to complement fragments. (medscape.com)
- The complement system consists of 7 serum and 9 membrane regulatory proteins, 1 serosal regulatory protein, and 8 cell membrane receptors that bind complement fragments. (medscape.com)
- Cell surface proteins have evolved which prevent EC damage by the cytotoxic defence system, decay-accelerating factor (DAF), protectin (CD59) and membrane cofactor protein (MCP). (biomedcentral.com)
- We now show that complement factor H-related protein 1 (FHR-1) and factor H-like protein 1 (FHL-1), proteins of the FH protein family that show amino acid sequence and regulatory function similarities with FH, also bind to Stx2. (leibniz-hki.de)
- C3 and factor B proteins were measured in culture supernatant by enzyme-linked immunosorbent assay and C3 and factor B transcripts in harvested cells by reverse transcriptase - polymerase chain reaction . (bvsalud.org)
- Cytokine induced upregulation of C3 and factor B proteins was always associated with the upregulation of levels of C3 and factor B mRNA . (bvsalud.org)
- thus, PIGA mutations lead to a deficiency of GPI-anchored proteins, such as complement decay-accelerating factor (also known as CD55) and CD59 glycoprotein (CD59), which are both complement inhibitors. (medscape.com)
- How do distinct transcriptional regulatory proteins coordinate their job with extrinsic factors and the microenvironment? (nih.gov)
- The active ingredient comprises plasma proteins such as albumin , immunoglobulins, other globulins, coagulation factors, complement proteins and protease inhibitors. (rxlist.com)
- Genes that encode the proteins of complement components or their isotypes are distributed throughout different chromosomes, with 19 genes comprising 3 significant complement gene clusters in the human genome. (medscape.com)
- The important components of this system are various cell membrane-associated proteins such as complement receptor 1 (CR1), complement receptor 2 (CR2), and decay accelerating factor (DAF). (medscape.com)
- for example, the proteins factor H and factor I inhibit the formation of the enzyme C3 convertase of the alternative pathway. (medscape.com)
Deficiency10
- Factor I deficiency in turn leads to low levels of complement component 3 (C3), factor B, factor H and properdin in blood, due to unregulated activation of C3 convertase, and to low levels of IgG, due to loss of iC3b and C3dg production. (wikipedia.org)
- Complement factor I deficiency is a disorder that affects the immune system. (medlineplus.gov)
- Some people with complement factor I deficiency have a kidney disorder called glomerulonephritis with isolated C3 deposits. (medlineplus.gov)
- Complement factor I deficiency can also be associated with autoimmune disorders such as rheumatoid arthritis or systemic lupus erythematosus (SLE). (medlineplus.gov)
- Complement factor I deficiency is caused by mutations in the CFI gene. (medlineplus.gov)
- Mutations in the CFI gene that cause complement factor I deficiency result in abnormal, nonfunctional, or absent complement factor I. The lack (deficiency) of functional complement factor I protein allows uncontrolled activation of the complement system. (medlineplus.gov)
- Baracho GV, Nudelman V, Isaac L. Molecular characterization of homozygous hereditary factor I deficiency. (medlineplus.gov)
- Grumach AS, Leitao MF, Arruk VG, Kirschfink M, Condino-Neto A. Recurrent infections in partial complement factor I deficiency: evaluation of three generations of a Brazilian family. (medlineplus.gov)
- Ponce-Castro IM, Gonzalez-Rubio C, Delgado-Cervino EM, Abarrategui-Garrido C, Fontan G, Sanchez-Corral P, Lopez-Trascasa M. Molecular characterization of Complement Factor I deficiency in two Spanish families. (medlineplus.gov)
- Cases of complement deficiency have helped defined the role of complement in host defense. (medscape.com)
Alternative pathway5
- Factor H binds to C3b, accelerates the decay of the alternative pathway C3-convertase and acts as a cofactor for the factor Imediated proteolyticinac-tivation of C3b. (biovendor.com)
- Depending on the nature of complement activators, the classic pathway, the alternative pathway, or the more recently discovered lectin pathway is activated predominantly to produce C3 convertase. (medscape.com)
- Stx2 was shown to activate complement via the alternative pathway, to bind factor H (FH) at short consensus repeats (SCRs) 6-8 and 18-20 and to delay and reduce FH cofactor activity on the cell surface. (leibniz-hki.de)
- Atypical hemolytic uremic syndrome (aHUS) is a disease associated with dysregulation of the immune complement system, especially of the alternative pathway (AP). (elsevierpure.com)
- In vitro activation of the alternative pathway of complement by settled grain dust. (cdc.gov)
Antibody3
- To study the effect of MAC on HMEC expression of DAF, EC monolayers were opsonised with IgG2a anti-endoglin monoclonal antibody, thus optimising complement fixation ability. (biomedcentral.com)
- Mouse anti Human Complement Factor H antibody, clone 028B-244.2.10X (10-10) recognizes human complement factor H which exists in 2 forms. (bio-rad-antibodies.com)
- Lectins activate the lectin pathway in a manner similar to the antibody interaction with complement in the classical pathway. (medscape.com)
Pathways5
- Activation of the complement pathways. (medscape.com)
- This prevents these components of the classical and of alternative complement pathways from forming a positive feedback loop. (bio-rad-antibodies.com)
- We are now focused on delineating the transcription factors and signaling pathways that are responsible for generating photoreceptors from retinal progenitor cells. (nih.gov)
- The complement cascade consists of 3 separate pathways that converge in a final common pathway. (medscape.com)
- Complement pathways and deficiencies. (medscape.com)
Inhibitors2
- Conventional protease inhibitors do not completely inactivate Factor I but they can do so if the enzyme is pre-incubated with its substrate: this supports the proposed rearrangement of the molecule upon binding to the substrate. (wikipedia.org)
- In conclusion, multiple interactions of key complement inhibitors FH, FHR-1 and FHL-1 with Stx2 corroborate our hypothesis of a direct role of complement in EHEC-associated HUS. (leibniz-hki.de)
Receptor3
- The factor I heavy chain has four domains: an FI membrane attack complex (FIMAC) domain, CD5 domain, and low density lipoprotein receptor 1 and 2 (LDLr1 and LDLr2) domains. (wikipedia.org)
- the heavy chain plays an inhibitory role in maintaining the enzyme inactive until it meets the complex formed by the substrate (either C3b or C4b) and a cofactor protein (Factor H, C4b-binding protein, complement receptor 1, and membrane cofactor protein). (wikipedia.org)
- Similarly, sEng is a truncated form of receptor for two subtypes of transforming growth factor beta (TGF β ) specifically, TGF β 1 and TGF β 2 which are highly expressed by vascular endothelial cells and syncytiotrophoblasts. (hindawi.com)
Excessive complement activation2
- Complement factor B (FB) mutant variants are associated with excessive complement activation in kidney diseases such as atypical hemolytic uremic syndrome (aHUS), C3 glomerulopathy and membranoproliferative glomerulonephritis (MPGN). (lu.se)
- Complement factor H (CFH), consisting of 20 domains called complement control protein (CCP1-20), downregulates the AP as a cofactor for mediating C3 inactivation by complement factor I. However, anomalies related to CFH are known to cause excessive complement activation and cytotoxicity. (elsevierpure.com)
Regulates complement2
- Complement factor I (factor I) is a protein of the complement system, first isolated in 1966 in guinea pig serum, that regulates complement activation by cleaving cell-bound or fluid phase C3b and C4b. (wikipedia.org)
- An intricate system regulates complement activity. (medscape.com)
Mutations2
- Loss of function mutations in the Complement Factor I gene lead to low levels of factor I which results in increased complement activity. (wikipedia.org)
- These results suggest that FD inhibition can effectively block complement overactivation induced by FB gain-of-function mutations. (lu.se)
Protein11
- Complement factor I, also known as C3b/C4b inactivator, is a protein that in humans is encoded by the CFI gene. (wikipedia.org)
- Then, factor I is cleaved by furin to yield the mature factor I protein, which is a disulfide-linked dimer of heavy chain (residues 19-335, 51 kDalton) and light chain (residues 340-583, 37 kDalton). (wikipedia.org)
- This gene provides instructions for making a protein called complement factor I. This protein helps regulate a part of the body's immune response known as the complement system . (medlineplus.gov)
- The unregulated activity of the complement system decreases blood levels of another complement protein called C3, reducing the immune system's ability to fight infections. (medlineplus.gov)
- Complement factor H, a 155 kDaplasma glycoprotein, is an essential regulatory protein that plays a critical role in the homeostasis of the complement system in plasma and in the protection of bystander host cells and tissues from damage by complement activation. (biovendor.com)
- In addition, factor H has multiple physiological activities acts as an extracellularmatrix component, binds to cellular receptors of the integrintype, and interacts with a wide selection of ligands, such as the C-reactive protein, thrombospondin, bone sialoprotein, osteopontin, and heparin. (biovendor.com)
- Complement factor H is a soluble AP suppressor that recognizes self-surfaces on autologous surfaces, either directly via particular glycosaminoglycan and sialic acid or indirectly via C-reactive protein (CRP), and operates in fluid phase. (imedpub.com)
- Interaction of Shiga toxin 2 with complement regulators of the factor H protein family. (leibniz-hki.de)
- Poolpol K, Orth-Höller D, Speth C, Zipfel PF, Skerka C, de Córdoba SR, Brockmeyer J, Bielaszewska M, Würzner R (2014) Interaction of Shiga toxin 2 with complement regulators of the factor H protein family. (leibniz-hki.de)
- NRL interacts with homeodomain protein CRX and numerous other regulatory factors to control expression of most rod-expressed genes. (nih.gov)
- These bacteria use the surface protein Usp2 to capture and incapacitate the major complement factor C3. (lu.se)
Damage by complement1
- How do endothelial cells (ECs) protect themselves against damage by complement, particularly when they are present at the interface between blood and inflamed tissue? (biomedcentral.com)
Accelerates the decay1
- DAF prevents the formation and accelerates the decay of complement 3 (C3) convertases, MCP binds to C3b and C4b promoting their degradation and CD59 inhibits the membrane-attack complex (MAC). (biomedcentral.com)
Serum7
- The most widely studied serum markers for PE, to date, are vascular endothelial growth factor (VEGF) and placental growth factor (PlGF). (hindawi.com)
- Factor H is secreted by the liver into the blood serum. (bio-rad-antibodies.com)
- Crain, SM, Bornstein, MB & Lennon, VA 1975, ' Depression of complex bioelectric discharges in cerebral tissue cultures by thermolabile complement-dependent serum factors ', Experimental Neurology , vol. 49, no. 1, pp. 330-335. (elsevierpure.com)
- Abolition of depression by preheating the sera, and restoration, in some cases,b y addition of fresh (unheated) guinea pig serum (10%) suggested that the effect was complement-dependent (see below). (elsevierpure.com)
- More direct demonstration of complement-dependence was difficult since many of the sera blocked bioelectric discharges even without addition of guinea pig serum. (elsevierpure.com)
- CspA-mediated binding of human factor H inhibits complement deposition and confers serum resistance in Borrelia burgdorferi. (ouhsc.edu)
- The effects of settled grain dust on the human serum complement cascade were investigated. (cdc.gov)
Deficiencies8
- Clinical significance of complement deficiencies. (medlineplus.gov)
- The dosage of Octaplas for replacement of multiple coagulation factors in patients with acquired deficiencies is 10 to 15 milliliters per kg. (rxlist.com)
- Deficiencies in the complement cascade can lead to overwhelming infection and sepsis. (medscape.com)
- Complement deficiencies are said to comprise between 1 and 10% of all primary immunodeficiencies. (medscape.com)
- [ 3 ] A registry of complement deficiencies has been established as a means to promote joint projects on treatment and prevention of diseases associated with defective complement function. (medscape.com)
- This article outlines some of the disease states associated with complement deficiencies and their clinical implications. (medscape.com)
- Deficiencies in complement predispose patients to infection via 2 mechanisms: (1) ineffective opsonization and (2) defects in lytic activity (defects in MAC). (medscape.com)
- Specific complement deficiencies are also associated with an increased risk of developing autoimmune disease, such as SLE. (medscape.com)
Inflammation4
- It is important in regulating the complement pathway, preventing unnecessary inflammation which can damage the host tissue. (bio-rad-antibodies.com)
- The complement system plays an important part in host defense and inflammation . (bvsalud.org)
- 4 , 6 - 9 Several factors, including inflammation, oxidative stress, and dyslipidemia, are considered decisive for the progression of atherosclerosis in ESRD. (lww.com)
- at the same time, the inflammation promoted by complement activation can result in cellular damage when not kept in check. (medscape.com)
Form a unique fingerprint1
- Dive into the research topics of 'Functional anatomy of complement Factor H'. Together they form a unique fingerprint. (ed.ac.uk)
Partial complement1
- Some new clinical entities are linked with partial complement defects. (medscape.com)
Inactivation2
- Binding of factor H to C3b increases its inactivation by factor I. Properdin stabilizes it, preventing its inactivation by factors H and I. The alternate pathway does not result in a truly nonspecific activation of complement because it requires specific types of compounds for activation. (medscape.com)
- Complement factor H functions as a cofactor in the inactivation of C3b by factor I. It makes C3b susceptible to cleavage by factor I, resulting in iC3b. (bio-rad-antibodies.com)
Overactivation1
- Atypical hemolytic uremic syndrome is caused by complement overactivation. (wikipedia.org)
Bind complement1
- We showed that one common strategy is to bind complement inhibitor C4BP, which leads to decreased opsonisation of bacteria with C3b impairing phagocytosis and allowing bacterial survival. (lu.se)
Hemolytic activity1
- Aliquots were analyzed for factor-B conversion and hemolytic activity. (cdc.gov)
Properdin1
- Exceptions are C1, factor D, and properdin. (medscape.com)
System10
- The complement system is a crucial component of the innate immunity against microbial infection. (biovendor.com)
- Due to the constant monitoring of its alternate channel, the complement system reacts promptly to threat (AP). (imedpub.com)
- The complement system functions as an interactive sequence, with one reaction leading to another in the form of a cascade. (medscape.com)
- The complement system has recently been found to be involved in the pathogenesis of EHEC-associated HUS. (leibniz-hki.de)
- The complement system is part of the innate immune system. (medscape.com)
- The complement system plays an important part in defense against pyogenic organisms. (medscape.com)
- In addition to playing an important role in host defense against infection, the complement system is a mediator in both the pathogenesis and prevention of immune complex diseases, such as systemic lupus erythematosus (SLE). (medscape.com)
- These findings underscore the duality of the complement system. (medscape.com)
- Knowledge about the complement system is expanding. (medscape.com)
- Although the complement system is part of the body's innate, relatively nonspecific defense against pathogens, its role is hardly primitive or easily understood. (medscape.com)
Gene2
- The gene for Factor I in humans is located on chromosome 4. (wikipedia.org)
- rs800292, rs1061170, rs1410996) in the complement factor H ( CFH ) gene, rs 11200638-SNP in the high temperature requirement A-1 ( HTRA1 ) gene, two SNPs (rs699947, rs2010963) in the vascular endothelial growth factor ( VEGF ) gene, and four SNPs (rs12948385, rs12150053, rs9913583, rs1136287) in the pigment epithelium-derived factor ( PEDF ) gene were evaluated. (dovepress.com)
Abnormal1
- The term "nocturnal" refers to the belief that hemolysis is triggered by acidosis during sleep and activates complement to hemolyze an unprotected and abnormal RBC membrane. (medscape.com)
Cytokines5
- This in turn results in an exponential production of multiple factors such as cytokines and growth factors leading to the clinical manifestations of PE [ 11 ]. (hindawi.com)
- To test the hypothesis that inflammatory cytokines and complement(C) MACs play a role in the expression of DAF, CD59 and MCP, and to investigate the intracellular signalling pathway involved in DAF expression. (biomedcentral.com)
- Synthesis of complement components C3 and factor B in human keratinocytes is differentially regulated by cytokines. (bvsalud.org)
- In skin the keratinocyte is the major cell type, it is known to produce two soluble complement components, C3 and factor B . In this study we investigated the regulation of synthesis of these components in foreskin keratinocytes by cytokines . (bvsalud.org)
- In conclusion, synthesis of C3 and factor B in keratinocytes is regulated by some cytokines , known to be produced by inflammatory cells and keratinocytes . (bvsalud.org)
Binds1
- Here, C3b binds to factor B that is cleaved by factor D to Bb. (medscape.com)
Innate1
- As a first line of defense against pathogens and a mediator between innate and adaptive immunity, complement is a particular focus of evasion strategies developed by pathogens. (lu.se)
Glycoprotein1
- Factor I is a glycoprotein heterodimer consisting of a disulfide linked heavy chain and light chain. (wikipedia.org)
Convertase3
- Mutagenesis was performed to study the effect of factor D (FD) inhibition on C3 convertase-induced FB cleavage, complement-mediated. (lu.se)
- In the first phase, a series of specific interactions leads to formation of intrinsic complement proteinase, termed C3 convertase. (medscape.com)
- Factor H also inhibits the formation of the C3bBb complex (C3 convertase) and increases the rate of dissociation of both C3 convertase and the (C3b)NBB complex (C5 convertase). (bio-rad-antibodies.com)
Renal diseases2
- Complement factor H has revealed an association with two different renal diseases, glomerulonephri-tisand atypical hemolytic uremicsyndrome (aHUS). (biovendor.com)
- Patients with aHUS are currently treated with eculizumab while there is no specific treatment for other complement-mediated renal diseases. (lu.se)
Diseases1
- In addition to the following diseases, low factor I is associated with recurrent bacterial infections in children. (wikipedia.org)
Cascade2
- How the immune response can activate the cascade process is still unknown but it is proposed to act in synergy with additional exacerbating factors such as predisposing maternal and ambient factors [ 12 ]. (hindawi.com)
- New studies point to the complex interplay between the complement cascade and adaptive immune response, and complement is also being studied in association with ischemic injury as a target of therapy. (medscape.com)
Intracellular1
- This indicated that, as expected, cytokine -induced enhancement in C3 and factor B levels was due to an increase in synthesis rather than their possible release from intracellular stores. (bvsalud.org)
Activation1
- The accumulation of anaphylatoxins (such as C5a) from complement activation might also have a role. (medscape.com)
Tissue1
- Locally synthesized complement may perform these functions at tissue and organ level. (bvsalud.org)
Receptors1
- Angiogenic factors and their receptors are important regulators of placental vascular development [ 13 ]. (hindawi.com)
Functional1
- We previously discovered that that Maf-family bZIP transcription factor NRL is critical for rod photoreceptor fate and functional differentiation, and that loss of NRL leads to S-cones instead of rods. (nih.gov)
Human3
- Crystal structure the crystal structure of human Factor I has been deposited as PDB: 2XRC. (wikipedia.org)
- Human keratinocytes were cultured in the presence of supernatant of activated peripheral blood mononuclear cells , interleukin-1alpha , interleukin-2 , interleukin-6 , transforming growth factor-beta1 , tumor necrosis factor-alpha , or interferon-gamma . (bvsalud.org)
- Another important mechanism by which bacteria resist human complement is the production of proteases that efficiently degrade complement components. (lu.se)
Soluble1
- Like sFlt1, soluble endoglin (sEng) is an antiangiogenic factor capable of inhibiting capillary tube formation in vitro [ 17 ]. (hindawi.com)
Resist1
- Pathogenic microorganisms, on the other hand, frequently resist complement assault and so escape destruction. (imedpub.com)
Disease2
- 1 It is a multifactorial disease with several identified genetic and environmental risk factors, including age, smoking, body mass index, hypertension, and others. (dovepress.com)
- So that suspect case of Ebola disease or suspect case of Ebola disease definition is a person with signs and symptoms compatible with Ebola disease and an epidemiological risk factor within 21 days before the onset of symptoms. (cdc.gov)
Clinical implications1
- Dysregulated factor I activity has clinical implications. (wikipedia.org)
Guinea2
Catalog1
- The Interaction With Host Pathway complements our catalog of research reagents including antibodies and ELISA kits against TNF, IL6, IL2, TLR2, TLR4. (novusbio.com)
Endothelial1
- Treatment is with dietary supplements, intravitreal injection of antivascular endothelial growth factor drugs, laser photocoagulation, photodynamic therapy, and low-vision devices. (msdmanuals.com)
Photodynamic therapy1
- This study aimed to demonstrate the phenotypic and genotypic factors associated with photodynamic therapy (PDT) for age-related macular degeneration (AMD). (dovepress.com)